Skip to main content
Erschienen in: Current Psychiatry Reports 2/2016

01.02.2016 | Substance Use and Related Disorders (F Levin and E Dakwar, Section Editors)

Cannabis and Psychosis: a Critical Overview of the Relationship

verfasst von: Charles Ksir, Carl L. Hart

Erschienen in: Current Psychiatry Reports | Ausgabe 2/2016

Einloggen, um Zugang zu erhalten

Abstract

Interest in the relationship between cannabis use and psychosis has increased dramatically in recent years, in part because of concerns related to the growing availability of cannabis and potential risks to health and human functioning. There now exists a plethora of scientific articles addressing this issue, but few provide a clear verdict about the causal nature of the cannabis-psychosis association. Here, we review recent research reports on cannabis and psychosis, giving particular attention to how each report provides evidence relating to two hypotheses: (1) cannabis as a contributing cause and (2) shared vulnerability. Two primary kinds of data are brought to bear on this issue: studies done with schizophrenic patients and studies of first-episode psychosis. Evidence reviewed here suggests that cannabis does not in itself cause a psychosis disorder. Rather, the evidence leads us to conclude that both early use and heavy use of cannabis are more likely in individuals with a vulnerability to psychosis. The role of early and heavy cannabis use as a prodromal sign merits further examination, along with a variety of other problem behaviors (e.g., early or heavy use of cigarettes or alcohol and poor school performance). Future research studies that focus exclusively on the cannabis-psychosis association will therefore be of little value in our quest to better understand psychosis and how and why it occurs.
Literatur
1.
Zurück zum Zitat Bagot KS, Milin R, Kaminer Y. Adolescent initiation of cannabis use and early-onset psychosis. Subst Abuse Off Publ Assoc Med Educ Res Subst Abuse. 2015 Mar 16;0. Bagot KS, Milin R, Kaminer Y. Adolescent initiation of cannabis use and early-onset psychosis. Subst Abuse Off Publ Assoc Med Educ Res Subst Abuse. 2015 Mar 16;0.
3.
Zurück zum Zitat Allegri F, Belvederi Murri M, Paparelli A, Marcacci T, Braca M, Menchetti M, et al. Current cannabis use and age of psychosis onset: a gender-mediated relationship? Results from an 8-year FEP incidence study in Bologna. Psychiatry Res. 2013;210(1):368–70.CrossRefPubMed Allegri F, Belvederi Murri M, Paparelli A, Marcacci T, Braca M, Menchetti M, et al. Current cannabis use and age of psychosis onset: a gender-mediated relationship? Results from an 8-year FEP incidence study in Bologna. Psychiatry Res. 2013;210(1):368–70.CrossRefPubMed
4.
Zurück zum Zitat Bahorik AL, Newhill CE, Eack SM. Neurocognitive functioning of individuals with schizophrenia: using and not using drugs. Schizophr Bull. 2014;40(4):856–67.PubMedCentralCrossRefPubMed Bahorik AL, Newhill CE, Eack SM. Neurocognitive functioning of individuals with schizophrenia: using and not using drugs. Schizophr Bull. 2014;40(4):856–67.PubMedCentralCrossRefPubMed
5.
Zurück zum Zitat Manrique-Garcia E, Zammit S, Dalman C, Hemmingsson T, Andreasson S, Allebeck P. Cannabis, schizophrenia and other non-affective psychoses: 35 years of follow-up of a population-based cohort. Psychol Med. 2012;42(06):1321–8.CrossRefPubMed Manrique-Garcia E, Zammit S, Dalman C, Hemmingsson T, Andreasson S, Allebeck P. Cannabis, schizophrenia and other non-affective psychoses: 35 years of follow-up of a population-based cohort. Psychol Med. 2012;42(06):1321–8.CrossRefPubMed
6.
Zurück zum Zitat Lejoyeux M, Basquin A, Koch M, Embouazza H, Chalvin F, Ilongo M. Cannabis use and dependence among French schizophrenic inpatients. Front Psychiatry [Internet]. 2014;5. Available from: http://journal.frontiersin.org/article/10.3389/fpsyt.2014.00082/abstract Lejoyeux M, Basquin A, Koch M, Embouazza H, Chalvin F, Ilongo M. Cannabis use and dependence among French schizophrenic inpatients. Front Psychiatry [Internet]. 2014;5. Available from: http://​journal.​frontiersin.​org/​article/​10.​3389/​fpsyt.​2014.​00082/​abstract
7.
Zurück zum Zitat Paruk S, Burns JK, Caplan R. Cannabis use and family history in adolescent first episode psychosis in Durban, South Africa. J Child Adolesc Ment Health. 2013;25(1):61–8.CrossRefPubMed Paruk S, Burns JK, Caplan R. Cannabis use and family history in adolescent first episode psychosis in Durban, South Africa. J Child Adolesc Ment Health. 2013;25(1):61–8.CrossRefPubMed
8.
Zurück zum Zitat Jessor R. Predicting time of onset of marijuana use: a developmental study of high school youth. J Consult Clin Psychol. 1976;44(1):125–34.CrossRefPubMed Jessor R. Predicting time of onset of marijuana use: a developmental study of high school youth. J Consult Clin Psychol. 1976;44(1):125–34.CrossRefPubMed
9.
Zurück zum Zitat Stone AL, Becker LG, Huber AM, Catalano RF. Review of risk and protective factors of substance use and problem use in emerging adulthood. Addict Behav. 2012;37(7):747–75.CrossRefPubMed Stone AL, Becker LG, Huber AM, Catalano RF. Review of risk and protective factors of substance use and problem use in emerging adulthood. Addict Behav. 2012;37(7):747–75.CrossRefPubMed
10.
Zurück zum Zitat Jessor R, Turbin MS. Parsing protection and risk for problem behavior versus pro-social behavior among US and Chinese adolescents. J Youth Adolesc. 2014;43(7):1037–51.CrossRefPubMed Jessor R, Turbin MS. Parsing protection and risk for problem behavior versus pro-social behavior among US and Chinese adolescents. J Youth Adolesc. 2014;43(7):1037–51.CrossRefPubMed
11.
Zurück zum Zitat American Psychiatric Association, American Psychiatric Association, editors. Diagnostic and statistical manual of mental disorders: DSM-5. 5th ed. Washington, D.C: American Psychiatric Association; 2013. 947 p American Psychiatric Association, American Psychiatric Association, editors. Diagnostic and statistical manual of mental disorders: DSM-5. 5th ed. Washington, D.C: American Psychiatric Association; 2013. 947 p
12.
Zurück zum Zitat Fuller Torrey E, Simmons W, Yolken RH. Is childhood cat ownership a risk factor for schizophrenia later in life? Schizophr Res. 2015;165(1):1–2.CrossRefPubMed Fuller Torrey E, Simmons W, Yolken RH. Is childhood cat ownership a risk factor for schizophrenia later in life? Schizophr Res. 2015;165(1):1–2.CrossRefPubMed
13.•
Zurück zum Zitat Broussard B, Kelley ME, Wan CR, Cristofaro SL, Crisafio A, Haggard PJ, et al. Demographic, socio-environmental, and substance-related predictors of duration of untreated psychosis (DUP). Schizophr Res. 2013;148(1–3):93–8. This study found that combining information from childhood maltreatment, school adjustment, and social adjustment predicted duration of untreated psychosis as well as did adolescent cannabis use. PubMedCentralCrossRefPubMed Broussard B, Kelley ME, Wan CR, Cristofaro SL, Crisafio A, Haggard PJ, et al. Demographic, socio-environmental, and substance-related predictors of duration of untreated psychosis (DUP). Schizophr Res. 2013;148(1–3):93–8. This study found that combining information from childhood maltreatment, school adjustment, and social adjustment predicted duration of untreated psychosis as well as did adolescent cannabis use. PubMedCentralCrossRefPubMed
14.
15.
Zurück zum Zitat Haller S, Curtis L, Badan M, Bessero S, Albom M, Chantraine F, et al. Combined grey matter VBM and white matter TBSS analysis in young first episode psychosis patients with and without cannabis consumption. Brain Topogr. 2013;26(4):641–7.CrossRefPubMed Haller S, Curtis L, Badan M, Bessero S, Albom M, Chantraine F, et al. Combined grey matter VBM and white matter TBSS analysis in young first episode psychosis patients with and without cannabis consumption. Brain Topogr. 2013;26(4):641–7.CrossRefPubMed
16.
Zurück zum Zitat McLaren JA, Silins E, Hutchinson D, Mattick RP, Hall W. Assessing evidence for a causal link between cannabis and psychosis: a review of cohort studies. Int J Drug Policy. 2010;21(1):10–9.CrossRefPubMed McLaren JA, Silins E, Hutchinson D, Mattick RP, Hall W. Assessing evidence for a causal link between cannabis and psychosis: a review of cohort studies. Int J Drug Policy. 2010;21(1):10–9.CrossRefPubMed
17.
Zurück zum Zitat van Nierop M, Janssens M, Genetic Risk OUtcome of Psychosis (GROUP) Investigators, Bruggeman R, Cahn W, de Haan L, et al. Evidence that transition from health to psychotic disorder can be traced to semi-ubiquitous environmental effects operating against background genetic risk. Clelland JD, editor. PLoS ONE. 2013;8(11):e76690. van Nierop M, Janssens M, Genetic Risk OUtcome of Psychosis (GROUP) Investigators, Bruggeman R, Cahn W, de Haan L, et al. Evidence that transition from health to psychotic disorder can be traced to semi-ubiquitous environmental effects operating against background genetic risk. Clelland JD, editor. PLoS ONE. 2013;8(11):e76690.
18.
Zurück zum Zitat Di Forti M, Marconi A, Carra E, Fraietta S, Trotta A, Bonomo M, et al. Proportion of patients in south London with first-episode psychosis attributable to use of high potency cannabis: a case-control study. Lancet Psychiatry. 2015;2(3):233–8.CrossRefPubMed Di Forti M, Marconi A, Carra E, Fraietta S, Trotta A, Bonomo M, et al. Proportion of patients in south London with first-episode psychosis attributable to use of high potency cannabis: a case-control study. Lancet Psychiatry. 2015;2(3):233–8.CrossRefPubMed
19.
Zurück zum Zitat Di Forti M, Sallis H, Allegri F, Trotta A, Ferraro L, Stilo SA, et al. Daily use, especially of high-potency cannabis, drives the earlier onset of psychosis in cannabis users. Schizophr Bull. 2014;40(6):1509–17.PubMedCentralCrossRefPubMed Di Forti M, Sallis H, Allegri F, Trotta A, Ferraro L, Stilo SA, et al. Daily use, especially of high-potency cannabis, drives the earlier onset of psychosis in cannabis users. Schizophr Bull. 2014;40(6):1509–17.PubMedCentralCrossRefPubMed
20.
Zurück zum Zitat Donoghue K, Doody GA, Murray RM, Jones PB, Morgan C, Dazzan P, et al. Cannabis use, gender and age of onset of schizophrenia: data from the AESOP study. Psychiatry Res. 2014;215(3):528–32.CrossRefPubMed Donoghue K, Doody GA, Murray RM, Jones PB, Morgan C, Dazzan P, et al. Cannabis use, gender and age of onset of schizophrenia: data from the AESOP study. Psychiatry Res. 2014;215(3):528–32.CrossRefPubMed
21.
Zurück zum Zitat Stefanis NC, Dragovic M, Power BD, Jablensky A, Castle D, Morgan VA. The effect of drug use on the age at onset of psychotic disorders in an Australian cohort. Schizophr Res. 2014;156(2–3):211–6.CrossRefPubMed Stefanis NC, Dragovic M, Power BD, Jablensky A, Castle D, Morgan VA. The effect of drug use on the age at onset of psychotic disorders in an Australian cohort. Schizophr Res. 2014;156(2–3):211–6.CrossRefPubMed
22.
Zurück zum Zitat Stone JM, Fisher HL, Major B, Chisholm B, Woolley J, Lawrence J, et al. Cannabis use and first-episode psychosis: relationship with manic and psychotic symptoms, and with age at presentation. Psychol Med. 2014;44(03):499–506.CrossRefPubMed Stone JM, Fisher HL, Major B, Chisholm B, Woolley J, Lawrence J, et al. Cannabis use and first-episode psychosis: relationship with manic and psychotic symptoms, and with age at presentation. Psychol Med. 2014;44(03):499–506.CrossRefPubMed
23.
Zurück zum Zitat Tosato S, Lasalvia A, Bonetto C, Mazzoncini R, Cristofalo D, De Santi K, et al. The impact of cannabis use on age of onset and clinical characteristics in first-episode psychotic patients. Data from the Psychosis Incident Cohort Outcome Study (PICOS). J Psychiatr Res. 2013;47(4):438–44.CrossRefPubMed Tosato S, Lasalvia A, Bonetto C, Mazzoncini R, Cristofalo D, De Santi K, et al. The impact of cannabis use on age of onset and clinical characteristics in first-episode psychotic patients. Data from the Psychosis Incident Cohort Outcome Study (PICOS). J Psychiatr Res. 2013;47(4):438–44.CrossRefPubMed
24.••
Zurück zum Zitat Degenhardt L, Ferrari AJ, Calabria B, Hall WD, Norman RE, McGrath J, et al. The global epidemiology and contribution of cannabis use and dependence to the global burden of disease: results from the GBD 2010 study. Brody JP, editor. PLoS ONE. 2013 Oct 24;8(10):e76635. This models the global burden of disease related to the influence of cannabis dependence and schizophrenia and points out that the overall health impact of this issue is very small. Degenhardt L, Ferrari AJ, Calabria B, Hall WD, Norman RE, McGrath J, et al. The global epidemiology and contribution of cannabis use and dependence to the global burden of disease: results from the GBD 2010 study. Brody JP, editor. PLoS ONE. 2013 Oct 24;8(10):e76635. This models the global burden of disease related to the influence of cannabis dependence and schizophrenia and points out that the overall health impact of this issue is very small.
25.
Zurück zum Zitat Dharmawardene V, Menkes DB. Substance use disorders in New Zealand adults with severe mental illness: descriptive study of an acute inpatient population. Aust Psychiatry. 2015;23(3):236–40.CrossRef Dharmawardene V, Menkes DB. Substance use disorders in New Zealand adults with severe mental illness: descriptive study of an acute inpatient population. Aust Psychiatry. 2015;23(3):236–40.CrossRef
27.•
Zurück zum Zitat Kendler KS, Lönn SL, Sundquist J, Sundquist K. Smoking and Schizophrenia in Population Cohorts of Swedish Women and Men: A Prospective Co-Relative Control Study. Am J Psychiatry. 2015 5;appiajp201515010126. This study does not address cannabis use, but its methods and findings for tobacco should be considered carefully by anyone attempting to study cannabis and schizophrenia. Kendler KS, Lönn SL, Sundquist J, Sundquist K. Smoking and Schizophrenia in Population Cohorts of Swedish Women and Men: A Prospective Co-Relative Control Study. Am J Psychiatry. 2015 5;appiajp201515010126. This study does not address cannabis use, but its methods and findings for tobacco should be considered carefully by anyone attempting to study cannabis and schizophrenia.
28.
Zurück zum Zitat McGrath JJ, Alati R, Clavarino A, Williams GM, Bor W, Najman JM, et al. Age at first tobacco use and risk of subsequent psychosis-related outcomes: a birth cohort study. Aust N Z J Psychiatry [Internet]. 2015; Available from: http://anp.sagepub.com/lookup/doi/10.1177/0004867415587341 McGrath JJ, Alati R, Clavarino A, Williams GM, Bor W, Najman JM, et al. Age at first tobacco use and risk of subsequent psychosis-related outcomes: a birth cohort study. Aust N Z J Psychiatry [Internet]. 2015; Available from: http://​anp.​sagepub.​com/​lookup/​doi/​10.​1177/​0004867415587341​
29.
Zurück zum Zitat Rabin RA, Giddens JL, George TP. Relationship between tobacco and cannabis use status in outpatients with schizophrenia. Am J Addict. 2014;23(2):170–5.CrossRefPubMed Rabin RA, Giddens JL, George TP. Relationship between tobacco and cannabis use status in outpatients with schizophrenia. Am J Addict. 2014;23(2):170–5.CrossRefPubMed
30.
Zurück zum Zitat Fernández-Calderón D, Fernández F, Ruiz-Curado S, Verdejo-García A, Lozano ÓM. Profiles of substance use disorders in patients of therapeutic communities: link to social, medical and psychiatric characteristics. Drug Alcohol Depend. 2015;149:31–9.CrossRefPubMed Fernández-Calderón D, Fernández F, Ruiz-Curado S, Verdejo-García A, Lozano ÓM. Profiles of substance use disorders in patients of therapeutic communities: link to social, medical and psychiatric characteristics. Drug Alcohol Depend. 2015;149:31–9.CrossRefPubMed
31.•
Zurück zum Zitat Sara GE, Burgess PM, Malhi GS, Whiteford HA, Hall WC. Stimulant and other substance use disorders in schizophrenia: prevalence, correlates and impacts in a population sample. Aust N Z J Psychiatry. 2014;48(11):1036–47. This large Australian study found greater risk ratios for schizophrenia associated with stimulant use or combined stimulant/cannabis use than for cannabis use alone. CrossRefPubMed Sara GE, Burgess PM, Malhi GS, Whiteford HA, Hall WC. Stimulant and other substance use disorders in schizophrenia: prevalence, correlates and impacts in a population sample. Aust N Z J Psychiatry. 2014;48(11):1036–47. This large Australian study found greater risk ratios for schizophrenia associated with stimulant use or combined stimulant/cannabis use than for cannabis use alone. CrossRefPubMed
32.
Zurück zum Zitat Auther AM, Cadenhead KS, Carrión RE, Addington J, Bearden CE, Cannon TD, et al. Alcohol confounds relationship between cannabis misuse and psychosis conversion in a high-risk sample. Acta Psychiatr Scand. 2015;132(1):60–8.CrossRefPubMed Auther AM, Cadenhead KS, Carrión RE, Addington J, Bearden CE, Cannon TD, et al. Alcohol confounds relationship between cannabis misuse and psychosis conversion in a high-risk sample. Acta Psychiatr Scand. 2015;132(1):60–8.CrossRefPubMed
33.••
Zurück zum Zitat Hartz SM, Pato CN, Medeiros H, Cavazos-Rehg P, Sobell JL, Knowles JA, et al. Comorbidity of severe psychotic disorders with measures of substance use. JAMA Psychiatry. 2014;71(3):248. I This very large study of severe psychosis found higher odds ratios for tobacco use, heavy alcohol use, and recreational drug use than for cannabis use. PubMedCentralCrossRefPubMed Hartz SM, Pato CN, Medeiros H, Cavazos-Rehg P, Sobell JL, Knowles JA, et al. Comorbidity of severe psychotic disorders with measures of substance use. JAMA Psychiatry. 2014;71(3):248. I This very large study of severe psychosis found higher odds ratios for tobacco use, heavy alcohol use, and recreational drug use than for cannabis use. PubMedCentralCrossRefPubMed
34.•
Zurück zum Zitat Nesvåg R, Knudsen GP, Bakken IJ, Høye A, Ystrom E, Surén P, et al. Substance use disorders in schizophrenia, bipolar disorder, and depressive illness: a registry-based study. Soc Psychiatry Psychiatr Epidemiol. 2015; This study took the unusual step of including a variety od psychiatric disorders and a variety of substance use in the same study. There was a clear association between cannabis use and schizophrenia, but this study makes it clear that this is not a unique relationship. Nesvåg R, Knudsen GP, Bakken IJ, Høye A, Ystrom E, Surén P, et al. Substance use disorders in schizophrenia, bipolar disorder, and depressive illness: a registry-based study. Soc Psychiatry Psychiatr Epidemiol. 2015; This study took the unusual step of including a variety od psychiatric disorders and a variety of substance use in the same study. There was a clear association between cannabis use and schizophrenia, but this study makes it clear that this is not a unique relationship.
35.
Zurück zum Zitat Arias F, Szerman N, Vega P, Mesias B, Basurte I, Morant C, et al. Abuse or dependence on cannabis and other psychiatric disorders. Madrid study on dual pathology prevalence. Actas Esp Psiquiatr. 2013;41(2):122–9.PubMed Arias F, Szerman N, Vega P, Mesias B, Basurte I, Morant C, et al. Abuse or dependence on cannabis and other psychiatric disorders. Madrid study on dual pathology prevalence. Actas Esp Psiquiatr. 2013;41(2):122–9.PubMed
36.
Zurück zum Zitat Chadwick B, Miller ML, Hurd YL. Cannabis use during adolescent development: susceptibility to psychiatric illness. Front Psychiatry [Internet]. 2013;4. Available from: http://journal.frontiersin.org/article/10.3389/fpsyt.2013.00129/abstract Chadwick B, Miller ML, Hurd YL. Cannabis use during adolescent development: susceptibility to psychiatric illness. Front Psychiatry [Internet]. 2013;4. Available from: http://​journal.​frontiersin.​org/​article/​10.​3389/​fpsyt.​2013.​00129/​abstract
37.
Zurück zum Zitat Lagerberg TV, Kvitland LR, Aminoff SR, Aas M, Ringen PA, Andreassen OA, et al. Indications of a dose–response relationship between cannabis use and age at onset in bipolar disorder. Psychiatry Res. 2014;2015(1):101–4.CrossRef Lagerberg TV, Kvitland LR, Aminoff SR, Aas M, Ringen PA, Andreassen OA, et al. Indications of a dose–response relationship between cannabis use and age at onset in bipolar disorder. Psychiatry Res. 2014;2015(1):101–4.CrossRef
38.
Zurück zum Zitat Guillem E, Arbabzadeh-Bouchez S, Vorspan F, Bellivier F. Comorbidity in 207 cannabis users in a specific outpatient setting. L’Encéphale. 2015;41 Suppl 1:S7–S12.CrossRefPubMed Guillem E, Arbabzadeh-Bouchez S, Vorspan F, Bellivier F. Comorbidity in 207 cannabis users in a specific outpatient setting. L’Encéphale. 2015;41 Suppl 1:S7–S12.CrossRefPubMed
39.••
Zurück zum Zitat Giordano GN, Ohlsson H, Sundquist K, Sundquist J, Kendler KS. The association between cannabis abuse and subsequent schizophrenia: a Swedish national co-relative control study. Psychol Med. 2014;3:1–8. This large registry study found that the majority of the association between cannabis and schizophrenia could be attributed to familial factors. Giordano GN, Ohlsson H, Sundquist K, Sundquist J, Kendler KS. The association between cannabis abuse and subsequent schizophrenia: a Swedish national co-relative control study. Psychol Med. 2014;3:1–8. This large registry study found that the majority of the association between cannabis and schizophrenia could be attributed to familial factors.
40.
Zurück zum Zitat Davis GP, Compton MT, Wang S, Levin FR, Blanco C. Association between cannabis use, psychosis, and schizotypal personality disorder: findings from the National Epidemiologic Survey on Alcohol and Related Conditions. Schizophr Res. 2013;151(1–3):197–202.CrossRefPubMed Davis GP, Compton MT, Wang S, Levin FR, Blanco C. Association between cannabis use, psychosis, and schizotypal personality disorder: findings from the National Epidemiologic Survey on Alcohol and Related Conditions. Schizophr Res. 2013;151(1–3):197–202.CrossRefPubMed
41.
Zurück zum Zitat Bossong MG, Mehta MA, van Berckel BNM, Howes OD, Kahn RS, Stokes PRA. Further human evidence for striatal dopamine release induced by administration of ∆9-tetrahydrocannabinol (THC): selectivity to limbic striatum. Psychopharmacology (Berl). 2015;232(15):2723–9.CrossRef Bossong MG, Mehta MA, van Berckel BNM, Howes OD, Kahn RS, Stokes PRA. Further human evidence for striatal dopamine release induced by administration of ∆9-tetrahydrocannabinol (THC): selectivity to limbic striatum. Psychopharmacology (Berl). 2015;232(15):2723–9.CrossRef
42.
Zurück zum Zitat Bioque M, García-Bueno B, Macdowell KS, Meseguer A, Saiz PA, Parellada M, et al. Peripheral endocannabinoid system dysregulation in first-episode psychosis. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol. 2013;38(13):2568–77.CrossRef Bioque M, García-Bueno B, Macdowell KS, Meseguer A, Saiz PA, Parellada M, et al. Peripheral endocannabinoid system dysregulation in first-episode psychosis. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol. 2013;38(13):2568–77.CrossRef
44.
Zurück zum Zitat Volk DW, Eggan SM, Horti AG, Wong DF, Lewis DA. Reciprocal alterations in cortical cannabinoid receptor 1 binding relative to protein immunoreactivity and transcript levels in schizophrenia. Schizophr Res. 2014;159(1):124–9.PubMedCentralCrossRefPubMed Volk DW, Eggan SM, Horti AG, Wong DF, Lewis DA. Reciprocal alterations in cortical cannabinoid receptor 1 binding relative to protein immunoreactivity and transcript levels in schizophrenia. Schizophr Res. 2014;159(1):124–9.PubMedCentralCrossRefPubMed
45.
Zurück zum Zitat Koenders L, Machielsen MWJ, van der Meer FJ, van Gasselt ACM, Meijer CJ, van den Brink W, et al. Brain volume in male patients with recent onset schizophrenia with and without cannabis use disorders. J Psychiatry Neurosci JPN. 2015;40(3):197–206.CrossRefPubMed Koenders L, Machielsen MWJ, van der Meer FJ, van Gasselt ACM, Meijer CJ, van den Brink W, et al. Brain volume in male patients with recent onset schizophrenia with and without cannabis use disorders. J Psychiatry Neurosci JPN. 2015;40(3):197–206.CrossRefPubMed
46.
Zurück zum Zitat Malchow B, Hasan A, Schneider-Axmann T, Jatzko A, Gruber O, Schmitt A, et al. Effects of cannabis and familial loading on subcortical brain volumes in first-episode schizophrenia. Eur Arch Psychiatry Clin Neurosci. 2013;263(S2):155–68.CrossRef Malchow B, Hasan A, Schneider-Axmann T, Jatzko A, Gruber O, Schmitt A, et al. Effects of cannabis and familial loading on subcortical brain volumes in first-episode schizophrenia. Eur Arch Psychiatry Clin Neurosci. 2013;263(S2):155–68.CrossRef
47.
Zurück zum Zitat Onwuameze OE, Nam KW, Epping EA, Wassink TH, Ziebell S, Andreasen NC, et al. MAPK14 and CNR1 gene variant interactions: effects on brain volume deficits in schizophrenia patients with marijuana misuse. Psychol Med. 2013;43(03):619–31.CrossRefPubMed Onwuameze OE, Nam KW, Epping EA, Wassink TH, Ziebell S, Andreasen NC, et al. MAPK14 and CNR1 gene variant interactions: effects on brain volume deficits in schizophrenia patients with marijuana misuse. Psychol Med. 2013;43(03):619–31.CrossRefPubMed
48.
Zurück zum Zitat Epstein KA, Kumra S. Altered cortical maturation in adolescent cannabis users with and without schizophrenia. Schizophr Res. 2015;162(1–3):143–52.CrossRefPubMed Epstein KA, Kumra S. Altered cortical maturation in adolescent cannabis users with and without schizophrenia. Schizophr Res. 2015;162(1–3):143–52.CrossRefPubMed
49.
Zurück zum Zitat Solowij N, Walterfang M, Lubman DI, Whittle S, Lorenzetti V, Styner M, et al. Alteration to hippocampal shape in cannabis users with and without schizophrenia. Schizophr Res. 2013;143(1):179–84.CrossRefPubMed Solowij N, Walterfang M, Lubman DI, Whittle S, Lorenzetti V, Styner M, et al. Alteration to hippocampal shape in cannabis users with and without schizophrenia. Schizophr Res. 2013;143(1):179–84.CrossRefPubMed
50.
Zurück zum Zitat Fischer AS, Whitfield-Gabrieli S, Roth RM, Brunette MF, Green AI. Impaired functional connectivity of brain reward circuitry in patients with schizophrenia and cannabis use disorder: effects of cannabis and THC. Schizophr Res. 2014;158(1–3):176–82.CrossRefPubMed Fischer AS, Whitfield-Gabrieli S, Roth RM, Brunette MF, Green AI. Impaired functional connectivity of brain reward circuitry in patients with schizophrenia and cannabis use disorder: effects of cannabis and THC. Schizophr Res. 2014;158(1–3):176–82.CrossRefPubMed
51.
Zurück zum Zitat Greenwood L, Broyd SJ, Croft R, Todd J, Michie PT, Johnstone S, et al. Chronic effects of cannabis use on the auditory mismatch negativity. Biol Psychiatry. 2014;75(6):449–58.CrossRefPubMed Greenwood L, Broyd SJ, Croft R, Todd J, Michie PT, Johnstone S, et al. Chronic effects of cannabis use on the auditory mismatch negativity. Biol Psychiatry. 2014;75(6):449–58.CrossRefPubMed
52.
Zurück zum Zitat Herzig DA, Sullivan S, Lewis G, Corcoran R, Drake R, Evans J, et al. Hemispheric language asymmetry in first episode psychosis and schizotypy: the role of cannabis consumption and cognitive disorganization. Schizophr Bull. 2015;41 Suppl 2:S455–64.CrossRefPubMed Herzig DA, Sullivan S, Lewis G, Corcoran R, Drake R, Evans J, et al. Hemispheric language asymmetry in first episode psychosis and schizotypy: the role of cannabis consumption and cognitive disorganization. Schizophr Bull. 2015;41 Suppl 2:S455–64.CrossRefPubMed
53.
Zurück zum Zitat Monteleone P, Di Filippo C, Fabrazzo M, Milano W, Martiadis V, Corrivetti G, et al. Flattened cortisol awakening response in chronic patients with schizophrenia onset after cannabis exposure. Psychiatry Res. 2014;215(2):263–7.CrossRefPubMed Monteleone P, Di Filippo C, Fabrazzo M, Milano W, Martiadis V, Corrivetti G, et al. Flattened cortisol awakening response in chronic patients with schizophrenia onset after cannabis exposure. Psychiatry Res. 2014;215(2):263–7.CrossRefPubMed
54.
Zurück zum Zitat Muller-Vahl K, Emrich H. Cannabis and schizophrenia: towards a cannabinoid hypothesis of schizophrenia. Exp Rev Neurother. 2008;8(7):1037–48.CrossRef Muller-Vahl K, Emrich H. Cannabis and schizophrenia: towards a cannabinoid hypothesis of schizophrenia. Exp Rev Neurother. 2008;8(7):1037–48.CrossRef
55.
Zurück zum Zitat Morena M, Patel S, Bains J, Hill, M. Neurobiological interactions between stress and the endocannabinoid system. Neuropsychopharmacol Rev. 2015 Morena M, Patel S, Bains J, Hill, M. Neurobiological interactions between stress and the endocannabinoid system. Neuropsychopharmacol Rev. 2015
58.
Zurück zum Zitat Aberg KA, Liu Y, Bukszár J, McClay JL, Khachane AN, Andreassen OA, et al. A comprehensive family-based replication study of schizophrenia genes. JAMA Psychiatry. 2013;70(6):573.CrossRefPubMed Aberg KA, Liu Y, Bukszár J, McClay JL, Khachane AN, Andreassen OA, et al. A comprehensive family-based replication study of schizophrenia genes. JAMA Psychiatry. 2013;70(6):573.CrossRefPubMed
59.
Zurück zum Zitat Power RA, Verweij KJH, Zuhair M, Montgomery GW, Henders AK, Heath AC, et al. Genetic predisposition to schizophrenia associated with increased use of cannabis. Mol Psychiatry. 2014;19(11):1201–4.PubMedCentralCrossRefPubMed Power RA, Verweij KJH, Zuhair M, Montgomery GW, Henders AK, Heath AC, et al. Genetic predisposition to schizophrenia associated with increased use of cannabis. Mol Psychiatry. 2014;19(11):1201–4.PubMedCentralCrossRefPubMed
60.••
Zurück zum Zitat Proal AC, Fleming J, Galvez-Buccollini JA, DeLisi LE. A controlled family study of cannabis users with and without psychosis. Schizophr Res. 2014;152(1):283–8. This well-designed study used a 2 × 2 comparison of cannabis use and psychosis, concluding that schizophrenia in cannabis users is likely due to familial risk rather than to cannabis exposure. PubMedCentralCrossRefPubMed Proal AC, Fleming J, Galvez-Buccollini JA, DeLisi LE. A controlled family study of cannabis users with and without psychosis. Schizophr Res. 2014;152(1):283–8. This well-designed study used a 2 × 2 comparison of cannabis use and psychosis, concluding that schizophrenia in cannabis users is likely due to familial risk rather than to cannabis exposure. PubMedCentralCrossRefPubMed
61.
Zurück zum Zitat Buchy L, Perkins D, Woods SW, Liu L, Addington J. Impact of substance use on conversion to psychosis in youth at clinical high risk of psychosis. Schizophr Res. 2014;156(2–3):277–80.PubMedCentralCrossRefPubMed Buchy L, Perkins D, Woods SW, Liu L, Addington J. Impact of substance use on conversion to psychosis in youth at clinical high risk of psychosis. Schizophr Res. 2014;156(2–3):277–80.PubMedCentralCrossRefPubMed
62.
Zurück zum Zitat Valmaggia LR, Day FL, Jones C, Bissoli S, Pugh C, Hall D, et al. Cannabis use and transition to psychosis in people at ultra-high risk. Psychol Med. 2014;44(12):2503–12.CrossRefPubMed Valmaggia LR, Day FL, Jones C, Bissoli S, Pugh C, Hall D, et al. Cannabis use and transition to psychosis in people at ultra-high risk. Psychol Med. 2014;44(12):2503–12.CrossRefPubMed
63.•
Zurück zum Zitat Niemi-Pynttäri JA, Sund R, Putkonen H, Vorma H, Wahlbeck K, Pirkola SP. Substance-induced psychoses converting into schizophrenia: a register-based study of 18,478 Finnish inpatient cases. J Clin Psychiatry. 2013;74(01):e94–9. A large study that found a particularly strong tendency for cannabis-induced psychosis to later convert to schizophrenia, although cannabis-induced psychosis was relatively infrequent. CrossRefPubMed Niemi-Pynttäri JA, Sund R, Putkonen H, Vorma H, Wahlbeck K, Pirkola SP. Substance-induced psychoses converting into schizophrenia: a register-based study of 18,478 Finnish inpatient cases. J Clin Psychiatry. 2013;74(01):e94–9. A large study that found a particularly strong tendency for cannabis-induced psychosis to later convert to schizophrenia, although cannabis-induced psychosis was relatively infrequent. CrossRefPubMed
64.
Zurück zum Zitat Hamilton I, Lloyd C, Hewitt C, Godfrey C. Effect of reclassification of cannabis on hospital admissions for cannabis psychosis: a time series analysis. Int J Drug Policy. 2014;25(1):151–6.CrossRefPubMed Hamilton I, Lloyd C, Hewitt C, Godfrey C. Effect of reclassification of cannabis on hospital admissions for cannabis psychosis: a time series analysis. Int J Drug Policy. 2014;25(1):151–6.CrossRefPubMed
65.
Zurück zum Zitat Hjorthøj CR, Fohlmann A, Larsen A-M, Gluud C, Arendt M, Nordentoft M. Specialized psychosocial treatment plus treatment as usual (TAU) versus TAU for patients with cannabis use disorder and psychosis: the CapOpus randomized trial. Psychol Med. 2013;43(07):1499–510.CrossRefPubMed Hjorthøj CR, Fohlmann A, Larsen A-M, Gluud C, Arendt M, Nordentoft M. Specialized psychosocial treatment plus treatment as usual (TAU) versus TAU for patients with cannabis use disorder and psychosis: the CapOpus randomized trial. Psychol Med. 2013;43(07):1499–510.CrossRefPubMed
66.••
Zurück zum Zitat Madigan K, Brennan D, Lawlor E, Turner N, Kinsella A, O’Connor JJ, et al. A multi-center, randomized controlled trial of a group psychological intervention for psychosis with comorbid cannabis dependence over the early course of illness. Schizophr Res. 2013;143(1):138–42. This well-controlled study examined the effect of an intervention designed to reduce cannabis use, and found no reduction in cannabis use and no effect on clinical outcomes. CrossRefPubMed Madigan K, Brennan D, Lawlor E, Turner N, Kinsella A, O’Connor JJ, et al. A multi-center, randomized controlled trial of a group psychological intervention for psychosis with comorbid cannabis dependence over the early course of illness. Schizophr Res. 2013;143(1):138–42. This well-controlled study examined the effect of an intervention designed to reduce cannabis use, and found no reduction in cannabis use and no effect on clinical outcomes. CrossRefPubMed
67.
Zurück zum Zitat Guilarte TR, Opler M, Pletnikov M. Is lead exposure in early life an environmental risk factor for Schizophrenia? Neurobiological connections and testable hypotheses. NeuroToxicology. 2012;33(3):560–74.PubMedCentralCrossRefPubMed Guilarte TR, Opler M, Pletnikov M. Is lead exposure in early life an environmental risk factor for Schizophrenia? Neurobiological connections and testable hypotheses. NeuroToxicology. 2012;33(3):560–74.PubMedCentralCrossRefPubMed
68.
Zurück zum Zitat Kendler KS, Ohlsson H, Mezuk B, Sundquist K, Sundquist J. A Swedish national prospective and co-relative study of school achievement at age 16, and risk for schizophrenia, other nonaffective psychosis, and bipolar illness. Schizophr Bull. 2015;sbv103. Kendler KS, Ohlsson H, Mezuk B, Sundquist K, Sundquist J. A Swedish national prospective and co-relative study of school achievement at age 16, and risk for schizophrenia, other nonaffective psychosis, and bipolar illness. Schizophr Bull. 2015;sbv103.
69.
Zurück zum Zitat Gosden NP. Violence of young criminals predicts schizophrenia: a 9-year register-based followup of 15-to 19-year-old criminals. Schizophr Bull. 2005;31(3):759–68.CrossRefPubMed Gosden NP. Violence of young criminals predicts schizophrenia: a 9-year register-based followup of 15-to 19-year-old criminals. Schizophr Bull. 2005;31(3):759–68.CrossRefPubMed
70.
Zurück zum Zitat Anwar S, Langstrom N, Grann M, Fazel S. Is arson the crime most strongly associated with psychosis?—a national case-control study of arson risk in schizophrenia and other psychoses. Schizophr Bull. 2011;37(3):580–6.PubMedCentralCrossRefPubMed Anwar S, Langstrom N, Grann M, Fazel S. Is arson the crime most strongly associated with psychosis?—a national case-control study of arson risk in schizophrenia and other psychoses. Schizophr Bull. 2011;37(3):580–6.PubMedCentralCrossRefPubMed
Metadaten
Titel
Cannabis and Psychosis: a Critical Overview of the Relationship
verfasst von
Charles Ksir
Carl L. Hart
Publikationsdatum
01.02.2016
Verlag
Springer US
Erschienen in
Current Psychiatry Reports / Ausgabe 2/2016
Print ISSN: 1523-3812
Elektronische ISSN: 1535-1645
DOI
https://doi.org/10.1007/s11920-015-0657-y

Weitere Artikel der Ausgabe 2/2016

Current Psychiatry Reports 2/2016 Zur Ausgabe

Eating Disorders (C Grilo, Section Editor)

Interventions for the Carers of Patients With Eating Disorders

Personality Disorders (C Schmahl, Section Editor)

Dreams and Nightmares in Personality Disorders

Psychiatry in Primary Care (BN Gaynes, Section Editor)

Identification and Management of Chronic Pain in Primary Care: a Review

Demenzkranke durch Antipsychotika vielfach gefährdet

23.04.2024 Demenz Nachrichten

Wenn Demenzkranke aufgrund von Symptomen wie Agitation oder Aggressivität mit Antipsychotika behandelt werden, sind damit offenbar noch mehr Risiken verbunden als bislang angenommen.

Weniger postpartale Depressionen nach Esketamin-Einmalgabe

Bislang gibt es kein Medikament zur Prävention von Wochenbettdepressionen. Das Injektionsanästhetikum Esketamin könnte womöglich diese Lücke füllen.

„Psychotherapie ist auch bei sehr alten Menschen hochwirksam!“

22.04.2024 DGIM 2024 Kongressbericht

Die Kombination aus Medikamenten und Psychotherapie gilt als effektivster Ansatz bei Depressionen. Das ist bei betagten Menschen nicht anders, trotz Besonderheiten.

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

22.04.2024 DGIM 2024 Nachrichten

Um Menschen nach der Flucht aus einem Krisengebiet bestmöglich medizinisch betreuen zu können, ist es gut zu wissen, welche Erkrankungen im jeweiligen Herkunftsland häufig sind. Dabei hilft eine Internetseite der CDC (Centers for Disease Control and Prevention).

Update Psychiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.